Acer Therapeutics Stock Price, News & Analysis

Acer Therapeutics Inc. (Nasdaq: ACER), based in Cambridge, MA, is a pioneering biotechnology company focused on developing repurposed and reformulated medicines to address ultra-orphan diseases with significant unmet medical needs. Acer's flagship product, OLPRUVA™ (sodium phenylbutyrate), was approved by the FDA in December 2022 and targets urea cycle disorders (UCDs), conditions that prevent the body from removing waste nitrogen, leading to serious health issues. OLPRUVA™ is now available in all dosage strengths and is supported by a dedicated patient support team through Navigator by Acer Therapeutics to ensure seamless prescription management and patient care.

In addition to OLPRUVA™, Acer is also developing EDSIVO™ (celiprolol) for vascular Ehlers-Danlos syndrome (vEDS) and has paused the development of ACER-801 (osanetant) for Vasomotor Symptoms (VMS) and other conditions. The company is actively engaged in discussions with major pharmacy benefits managers and government payers to secure insurance coverage for OLPRUVA™, which is expected to be included in commercial insurance plans by the second half of 2023 and Medicaid programs by the third quarter of 2023.

Acer has recently regained worldwide rights to OLPRUVA™ (excluding Geographical Europe) from Relief Therapeutics, allowing the company to reinvest more capital into potential lifecycle expansion opportunities. This move aims to maximize the global commercialization of OLPRUVA™, ensuring it reaches as many patients in need as possible.

The company's strategic focus on rare diseases underscores its commitment to transforming the lives of patients with limited treatment options, leveraging innovative solutions like OLPRUVA™ to address critical health challenges globally.